For example, drugs that target the PI3K/Akt/mTOR pathway have shown activity in a range of cancers, including renal cell carcinoma [9] and triple-negative breast cancer (TNBC) [10], where conventional anti-cancer therapies have failed. The gene discussed is AKT1; the disease is cancer.